Items tagged with Drug-resistant TB
Activists across the world demand urgent action to improve access to lifesaving TB medicine, bedaquiline (post with simple image)
Communities affected by TB everywhere have a right to benefit from scientific progress, including access to short-course, bedaquiline-based treatment regimens for drug-resistant TB.
Field guide for managing drug-resistant TB in pregnant and peripartum people (post with simple image)
The Sentinel Project on Pediatric Drug-Resistant Tuberculosis releases a guide meant to support the care of pregnant and peripartum people with drug-resistant TB and the neonates born to them.
Response to TB treatment trials results published and presented during the 2022 Union World Conference on Lung Health (post with simple image)
Statement by Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB)
New MSF report warns that major opportunity to increase access to newer, safer DR-TB drugs is at risk (post with simple image)
With newer TB drugs to go off patent in 2023, MSF calls on Johnson & Johnson, Otsuka, and TB Alliance to remove additional barriers blocking generic manufacturers from entering the market.
WHO announces landmark changes in treatment of drug-resistant TB (post with simple image)
The World Health Organization releases updated guidelines and a supporting operational handbook on the treatment of drug-resistant TB featuring major improvements in treatment options for people with multidrug-resistant or rifampicin-resistant TB.
Urgent action necessary to improve equitable access to bedaquiline-based regiments and achieve 1/4/6×24 (post with simple image)
Advocates urge Johnson & Johnson to correct its course and stop blocking entry of generic versions of bedaquiline into the global market and into countries.
India must reject Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug bedaquiline (post with simple image)
Médecins Sans Frontières urges the Indian Patent Office to reject the secondary patent application filed by Johnson & Johnson to prevent the company from extending its monopoly on bedaquiline beyond the primary patent’s expiry in July 2023.
The 1/4/6×24 Campaign Coalition welcomes India’s rejection of Johnson & Johnson’s patent evergreening tactic (post with simple image)
The Indian Patent Office takes a laudable step that will pave the way for generic manufacturing of a key TB drug.
Advocacy campaign and petition call for universal access to six-month drug-resistant TB cures (post with simple image)
The Fast Track the Cure campaign demands universal access to six-month drug-resistant TB cure by 2024.
MSF demands J&J give up its patent monopoly on TB drug to put lives over profits (post with simple image)
Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many.
Page 108 of 108 · Total posts: 0
←First 107 108